Conditions: Endometrial Carcinoma
Keywords: Endometrial Cancer Endometrial Carcinoma Aromatase Inhibitor Letrozole Femara
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 43
Healthy volunteers: no

Brief summary:
Some cases of endometrial cancer are dependent on estrogen for their growth. Letrozole blocks estrogen production in the body. The purpose of this study is to determine if the investigators can predict which patients might benefit from Letrozole treatment by studying the many different forms of the estrogen receptor molecule that exist within the cancer tissues. To participate in this study, the patients must be 40 years of age or older and have biopsy-proven endometrial carcinoma, either well differentiated or moderately differentiated forms. Also, to be eligible to participate in this study, the patients need to be healthy enough to have a hysterectomy. If the patients are less than age 60, they will need a blood test (FSH) to confirm that they have gone into menopause.

Detailed description:

Arms:
arm 1: letrozole 2.5 mg PO daily for 2-3 weeks prior to hysterectomy. arm 2: no treatemtn prior to hysterectomy

Interventions: intervention 1: Letrozole
Intervention descriptions: intervention 1: 2.5 mg daily from the day of enrollment to the day before surgery, generally about 3 weeks

Protocol document: